References
<A NAME="RD16402ST-1A">1a</A>
Hopkins FG.
Nature (London)
1889,
40:
335
<A NAME="RD16402ST-1B">1b</A>
Hopkins FG.
Nature (London)
1891,
45:
197
<A NAME="RD16402ST-1C">1c</A>
Hopkins FG.
Nature (London)
1892,
45:
581
<A NAME="RD16402ST-2">2</A>
Mitchell HK.
Snell EE.
Williams RJ.
J. Am. Chem. Soc.
1941,
63:
2284
<A NAME="RD16402ST-3">3</A>
Scott JM.
Weir DG.
Kirke P.
In Folate and Neural Tube defects. Folate in
Health and Disease
Chap. 12:
Bailey
L. B., Marcel Dekker;
New York:
1994.
p.329
<A NAME="RD16402ST-4A">4a</A>
Taylor EC.
Palmer DC.
George TJ.
Fletcher SR.
Tseng CP.
Harrington PJ.
Beardsley GP.
J. Org. Chem.
1983,
48:
4852
<A NAME="RD16402ST-4B">4b</A>
DeGraw JI.
Christie PH.
Colwell WT.
Sirotnak FM.
J.
Med. Chem.
1992,
35:
320
<A NAME="RD16402ST-4C">4c</A>
Borrell JI.
Teixidó J.
Matallana JL.
Martínez-Teipel B.
Colominas C.
Costa M.
Balcells M.
Schuler E.
Castillo MJ.
J. Med. Chem.
2001,
44:
2366
<A NAME="RD16402ST-5">5</A>
Grivsky EM.
Lee S.
Sigel CW.
Duch DS.
Nichol CA.
J.
Med. Chem.
1980,
23:
327
<A NAME="RD16402ST-6A">6a</A>
Matsumoto J.
Minami S.
J.
Med. Chem.
1975,
18:
74
<A NAME="RD16402ST-6B">6b</A>
Suzuki N.
Chem.
Pharm. Bull.
1980,
28:
761
<A NAME="RD16402ST-6C">6c</A>
Oakes V.
Rydon HN.
J. Chem. Soc.
1956,
4433
<A NAME="RD16402ST-6D">6d</A>
DeGraw JI.
Kisliuk RL.
Gaumont Y.
Baugh CM.
J.
Med. Chem.
1974,
17:
470
<A NAME="RD16402ST-6E">6e</A>
Zakharov AV.
Gavrilov MY.
Novoselova GN.
Vakhrin MI.
Konshin ME.
Khim-Farm. Zh.
1996,
30:
39
<A NAME="RD16402ST-7">7</A>
Deyanov AB.
Niyazov RK.
Nazmetdinov FY.
Syropyatov BY.
Kolla VE.
Konshin ME.
Khim-Farm. Zh.
1991,
25:
26
<A NAME="RD16402ST-8">8</A>
Heckler RE, and
Jourdan GP. inventors; Eur. Patent 414 386.
; Chem. Abstr. 1991, 115, 71630
<A NAME="RD16402ST-9">9</A>
Bagley MC.
Hughes DD.
Lloyd R.
Powers VEC.
Tetrahedron
Lett.
2001,
42:
6585
<A NAME="RD16402ST-10">10</A>
Bagley MC.
Dale JW.
Hughes DD.
Ohnesorge M.
Phillips NG.
Bower J.
Synlett
2001,
1523
<A NAME="RD16402ST-11">11</A>
Bagley MC.
Singh N.
Chem. Commun.
2001,
2438
<A NAME="RD16402ST-12">12</A>
Quiroga J.
Cisneros C.
Insuasty B.
Abonía R.
Nogueras M.
Sánchez A.
Tetrahedron Lett.
2001,
42:
5625
<A NAME="RD16402ST-13">13</A>
In a typical experimental procedure,
a mixture of 1,3-diaminopyrimidin-4-one 1 (0.20
g, 1.6 mmol), benzaldehyde (0.34 g, 3.2 mmol), ethyl acetoacetate
(0.41 g, 3.2 mmol) and zinc(II) bromide (0.072 g, 0.32 mmol) in
DMSO (7 mL) was irradiated for 20 min in a self-tunable CEM microwave synthesizer
at 160 °C (initial power 30 W) and then allowed to cool.
Water (25 mL) was added and the solution was left to stand for 5-6
h. The precipitated solid was filtered and washed with ethyl acetate
to give 5-deaza-5-dihydropterin (3a) (0.38
g, 80%) as a pale yellow solid, mp 179-180 °C (Found:
MH+, 327.1454. C17H18N4O3 requires
MH, 327.1457); IR (KBr)/cm-1:
3317, 3206, 2936, 1660, 1599, 1515, 1455, 1367, 1285, 1224, 1106,
1024; 1H NMR (DMSO-d
6;
400 MHz) δ (ppm) 10.34 (1 H, 3, 3-H), 9.06 (1 H, s, 8-H),
7.24-7.00 (5 H, m, PhH), 6.27 (2 H, s, NH2),
4.82 (1 H, s, 5-H), 3.94 (2 H, q, J = 7.0
Hz, CH2), 2.31 (3 H, s,
7-Me), 1.10 (3 H, t, J = 7.0 Hz, Me); 13C
NMR (DMSO-d
6; 100
MHz) δ (ppm) 167.2 (C), 161.8 (C), 154.4 (C), 154.3 (C),
148.5 (C), 147.5 (C), 128.0 (CH), 127.6 (CH), 125.9 (CH), 101.5
(C), 91.4 (C), 59.2 (CH), 36.8 (CH2), 18.8 (Me), 14.5
(Me); m/z (APcI) 327 (MH+,
100%), 79 (67).